Jennifer N. Brudno, an Associate Research Physician at the National Cancer Institute, shares her expertise on CAR T-cell therapy. The discussion highlights how genetically engineered T cells specifically target and kill tumor cells, showing promise against various B cell malignancies. Brudno also delves into the side effects, like cytokine release syndrome and neurological toxicities, while addressing FDA concerns over secondary malignancies. Plus, logistical challenges and advancements in making these therapies more accessible are explored, painting a comprehensive picture of CAR T-cell therapy's impact.
